Patents by Inventor Keith A. CANADA

Keith A. CANADA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY MOLECULES FOR CANCER TREATMENT
    Publication number: 20240124581
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: September 1, 2023
    Publication date: April 18, 2024
    Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAAF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, Jr., Haiguang XIAO, Danlin YANG
  • ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES
    Publication number: 20240060064
    Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Application
    Filed: September 14, 2023
    Publication date: February 22, 2024
    Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
  • Engineered phosphopentomutase variant enzymes
    Patent number: 11795445
    Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: October 24, 2023
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
  • Antibody molecules for cancer treatment
    Patent number: 11795219
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: October 24, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
  • Anti-BAFF antibodies
    Patent number: 11370818
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 28, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • ANTI-CD40 ANTIBODIES
    Publication number: 20220153857
    Abstract: The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 19, 2022
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias Litzenburger, Sanjaya Singh
  • Anti-CD40 antibodies
    Patent number: 11242394
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • ENGINEERED PURINE NUCLEOSIDE PHOSPHORYLASE VARIANT ENZYMES
    Publication number: 20220010316
    Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 13, 2022
    Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark A. Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay H. Russell, Keith A. Canada
  • Engineered purine nucleoside phosphorylase variant enzymes
    Patent number: 11162105
    Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: November 2, 2021
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay Russell, Keith A. Canada
  • ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES
    Publication number: 20210261940
    Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Application
    Filed: May 10, 2021
    Publication date: August 26, 2021
    Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
  • ANTI-IL-23 ANTIBODIES
    Publication number: 20210198355
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: October 9, 2020
    Publication date: July 1, 2021
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
  • Engineered phosphopentomutase variant enzymes
    Patent number: 11034948
    Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 15, 2021
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant Murphy, Nicholas M. Marshall, Jay Russell, Keith A. Canada
  • Antibody molecules for cancer treatment
    Patent number: 11028169
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: June 8, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
  • ANTIBODY MOLECULES FOR CANCER TREATMENT
    Publication number: 20210095020
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: May 11, 2020
    Publication date: April 1, 2021
    Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAFF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, JR., Haiguang XIAO, Danlin YANG
  • ANTI IL-36R ANTIBODIES
    Publication number: 20200231684
    Abstract: The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: December 17, 2019
    Publication date: July 23, 2020
    Inventors: Su-Ellen BROWN, Keith CANADA, Lukasz CHLEWICKI, Michael HOWELL, Detlev MENNERICH, Joseph Robert WOSKA, JR.
  • Anti IL-36R antibodies
    Patent number: 10550189
    Abstract: The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 4, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Su-Ellen Brown, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, Jr.
  • ENGINEERED PURINE NUCLEOSIDE PHOSPHORYLASE VARIANT ENZYMES
    Publication number: 20200010834
    Abstract: The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 9, 2020
    Inventors: Scott J. Novick, Nikki Dellas, Vesna Mitchell, Da Duan, Jovana Nazor, Oscar Alvizo, Auric Anthony Sowell-Kantz, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Nicholas M. Marshall, Jay Russell, Keith A. Canada
  • ENGINEERED PHOSPHOPENTOMUTASE VARIANT ENZYMES
    Publication number: 20200010823
    Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 9, 2020
    Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant Murphy, Nicholas M. Marshall, Jay Russell, Keith A. Canada
  • NOVEL ANTI-BAFF ANTIBODIES
    Publication number: 20190309034
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
  • Anti-BAFF antibodies
    Patent number: 10377804
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao